TCRT should sell for no less than $20B. In a year, that may seem like a bargain. The initial targets in patients 1 and 2 were successfully addressed. The highly stringent FDA trial protocols do not allow for multiple targets at this point or recognition of peripheral tumor reduction. The trial design is highly specific and was met, in my opinion. The patient population is the most vulnerable and likely to fail which delivers terrible optics in the face of promising results. I pray for those patients as they had little hope for complete remission. I'm hopeful TCRT results on the targeted tumors and types has raised awareness within the immuno-oncology space as to the potential TCRT brings.
I'm incredibly unhappy with this raise. When the CEO says publicly the company has many financing options and interested partners, it is a gut punch to loyal, long-term, retail shareholders to raise capital in the worst possible scenario. I'm impressed with Boyle's cost-cutting, refocusing the company, and communications. Until now. This capital raise sucks balls and contradicts the direction and comments he has clearly stated in recent weeks. I feel deceived and suckered. Period.
It is unthinkable TCRT stated they had many favorable options on the table only to find they opted for among the worst possible options.